Alphatec’s Arsenal(TM) Spinal Fixation System Further Expanded to Address Broader Market
22 Septembre 2015 - 2:46AM
Arsenal™ Osteotomy Instrument Set
Launched to Support Complex Spinal
Cases Featured at NASS Booth
#1147
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a global provider of spinal fusion
technologies, announced today that the Company has launched its
Arsenal Osteotomy Instrument Set, further expanding the Arsenal
Spinal Fixation System launched earlier this year. The
Arsenal Osteotomy Instrument Set is a foundational component
supporting Alphatec’s Arsenal Deformity pipeline program that is
targeted for beta launch in the first quarter of 2016. The
Company is showcasing Arsenal and the Arsenal Osteotomy Instrument
Set, as well its portfolio of products at the upcoming North
American Spine Society (NASS) Annual Meeting being held at
McCormick Place West, Chicago, Illinois, from October 14th - 16th,
2015. Alphatec Spine will be located in booth number 1147.
Robert Eastlack, M.D., a board-certified orthopedic surgeon
specializing in complex spinal conditions including spinal
deformity, spinal reconstructions and revisions at Scripps Green
Hospital, La Jolla, California, shares, “The Arsenal Osteotomy
Instrument Set represents a great statement regarding Alphatec’s
commitment to its deformity surgeons.” Dr. Eastlack
successfully performed surgery on the first patient using the new
Arsenal Osteotomy Instrument Set with the Arsenal Spinal Fixation
System in early September.
The Arsenal Osteotomy Instrument Set is the latest extension to
Arsenal, Alphatec’s new and innovative spinal fixation system.
Developed to support complex spinal cases, the Arsenal
Osteotomy Instrument Set was thoughtfully designed to provide
procedural efficiency, ergonomic instrumentation and multiple
instrument options to accommodate anatomical diversity. This
comprehensive instrument set supports posterior column osteotomies,
pedicle subtraction osteotomies and vertebral column
resections. Many of these procedures are necessary when
addressing complex spine cases, including deformity, which the
Company estimates to be a $650M worldwide market. The Arsenal
Osteotomy Instrument Set represents a milestone achievement
supporting the Company’s Arsenal Deformity pipeline program.
“Alphatec continues to focus on innovation that further enhances
the surgeon and patient surgical experiences,” said Jim Corbett,
President and Chief Executive Officer of Alphatec Spine.
“Continuing to expand the Arsenal platform to capture a broader
surgeon market is a key component of our corporate strategy.
Launching the new osteotomy set is a direct result of our execution
of that strategy. We are excited about the prospects for
Arsenal and the Arsenal Osteotomy Instrument Set as it provides a
prelude into our deformity program in Q1 of 2016.”
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary
of Alphatec Holdings, Inc., is a global medical device company that
designs, develops, manufactures and markets spinal fusion
technology products and solutions for the treatment of spinal
disorders associated with disease and degeneration, congenital
deformities and trauma. The Company's mission is to improve lives
by delivering advancements in spinal fusion technologies. The
Company and its affiliates market products in the U.S. and
internationally via a direct sales force and independent
distributors.
Additional information can be found at
www.alphatecspine.com.
About the North American Spine Society
(NASS)
The North American Spine Society is a global
multidisciplinary medical society that utilizes education, research
and advocacy to foster the highest quality, ethical, value-based
and evidence-based spine care for patients. The society is
comprised of almost 9000 members worldwide from disciplines
including orthopedic surgery, neurosurgery, physical medicine and
rehabilitation, pain management, physical/occupational therapy,
anesthesiology, radiology and other health care professionals
focused on the spine.
Additional information can be found at
www.nassannualmeeting.org.
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no
assurance that actual results or business conditions will not
differ materially from those projected or suggested in such
forward-looking statements as a result of various factors.
Forward-looking statements include the Company's ability to achieve
profitable growth; the Company’s ability to achieve both domestic
and international growth and future profitability. The words
"believe," "will," "should," "expect," "intend," "estimate" and
"anticipate," variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to; the
uncertainty of success in developing new products or products
currently in Alphatec Spine's pipeline within forecast timeframes,
or at all, including without limitation the products discussed in
this press release; failure to achieve acceptance of Alphatec
Spine's products by the surgeon community, including without
limitation the products discussed in this press release;
Alphatec Spine's ability to develop and expand its U.S.
and/or global revenues; continuation of favorable third party payor
reimbursement for procedures performed using Alphatec Spine's
products, including the products discussed in this press release;
unanticipated expenses or liabilities or other adverse events
affecting cash flow or Alphatec Spine's ability to successfully
control its costs or achieve profitability; uncertainty of
additional funding; Alphatec Spine's ability to compete with other
competing products and with emerging new technologies; product
liability exposure; an unsuccessful outcome in any material
litigation in which the Company is a defendant; patent infringement
claims and claims related to Alphatec Spine's intellectual
property. Please refer to the risks detailed from time to
time in Alphatec Spine's SEC reports, including its Annual Report
Form 10-K, as well as other filings on Form 10-Q and periodic
filings on Form 8-K. Alphatec Spine disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise, unless required by law.
CONTACT: Investor/Media Contact:
Christine Zedelmayer
Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024